4ZXY

FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione

4ZXY の概要

• エントリーDOI: 10.2210/pdb4zxy/pdb
• 関連するPDBエントリー: 4ZXX
• 分子名称: Coagulation factor VIIa heavy chain, Coagulation factor VIIa light chain, (2R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione, ... (7 entities in total)
• 機能のキーワード: glycoprotein, hydrolase, serine protease, plasma, blood coagulation factor, protein inhibitor complex, calcium-binding, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• 由来する生物種: Homo sapiens (Human); 詳細
• 細胞内の位置: Secreted: P08709 P08709
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 35019.99

構造登録者

Wei, A. (登録日: 2015-05-20, 公開日: 2015-07-22, 最終更新日: 2024-11-20)

主引用文献

Priestley, E.S.,Cheney, D.L.,DeLucca, I.,Wei, A.,Luettgen, J.M.,Rendina, A.R.,Wong, P.C.,Wexler, R.R.
Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.
J.Med.Chem., 58:6225-6236, 2015

PubMed Abstract: On the basis of a crystal structure of a phenylpyrrolidine lead and subsequent molecular modeling results, we designed and synthesized a novel series of macrocyclic FVIIa inhibitors. The optimal 16-membered macrocycle was 60-fold more potent than an acyclic analog. Further potency optimization by incorporation of P1' alkyl sulfone and P2 methyl groups provided a macrocycle with TF/FVIIa Ki = 1.6 nM, excellent selectivity against a panel of seven serine proteases, and FVII-deficient prothrombin time EC2x = 1.2 μM. Discovery of this potent, selective macrocyclic scaffold opens new possibilities for the development of orally bioavailable FVIIa inhibitors.

PubMed: 26151189
DOI: 10.1021/acs.jmedchem.5b00788

実験手法

X-RAY DIFFRACTION (2.06 Å)